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The National Eye Institute (NEI) hosted a workshop on November 19, 2014, as part of the
Audacious Goals Initiative (AGI), an NEI-led effort to rapidly expand therapies for eye diseases
through coordinated research funding. The central audacious goal aims to demonstrate by
2025 the restoration of usable vision in humans through the regeneration of neurons and
neural connections in the eye and visual system. This workshop focused on identifying
promising strategies for optic nerve regeneration. Its principal objective was to solicit input
on future AGI-related funding announcements, and specifically to ask, where are we now in
our scientific progress, and what progress should we reach for in the coming years? A full
report was generated as a white paper posted on the NEI Web site; this report summarizes the
discussion and outcomes from the meeting and serves as guidance for future funding of
research that focuses on optic nerve regeneration.
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Injury to or neurodegeneration of the optic nerve underliesvision loss in many diseases, including glaucoma, ischemic
and traumatic optic neuropathies, as well as retinal artery or
vein occlusions, and many others. Normally, in humans and
indeed in all mammals, there is no regenerative response, and
the failure of injured or degenerating retinal ganglion cells
(RGCs) to reconnect their axons through the optic nerve to
their natural targets in the brain explains the irreversibility of
such vision loss. A full white paper was published by these
authors and is available on the National Eye Institute (NEI) Web
site (in the public domain; available at https://nei.nih.gov/
audacious/optic_nerve).
The NEI’s Audacious Goals Initiative (AGI) program was
initiated in 2012, searching for big ideas to bring the energy of
the eye and vision research community into a chosen single
audacious goal: to restore vision by regenerating neurons and
their neural connections in the eye and visual system. To
understand progress to date in the sciences relevant to optic
nerve regeneration, and more specifically to identify focal areas
for funding, the NEI convened a workshop in November 2014
in Washington, DC. Participants (see appendix) represented a
variety of research areas relevant to optic nerve regeneration,
from developmental neurobiology to visual processing. Over
the course of a 4-hour roundtable discussion, the workshop
reviewed the current state of the science and addressed
knowledge gaps in and barriers to scientific progress (Tables
1 and 2), and identified key areas for discovery research.
STEPS TO OPTIC NERVE REGENERATION
What will it take to restore vision in optic neuropathies, and
what must happen to rescue an injured or dying RGC?
Workshop participants outlined steps necessary for promoting
successful optic nerve regeneration and restoration of vision.
RGC Survival
Survival is obviously a requirement for cellular or axon
regeneration; thus, preventing RGCs from degeneration and
subsequent death in the face of injury or disease is a critical first
step. Retinal ganglion cell response to insult was also discussed,
as the molecular pathophysiology of different insults, be they
glaucomatous, ischemic, traumatic, inflammatory, or others, is
still the subject of intense investigation. Although such
questions hold great promise, developing therapeutic ap-
proaches to restore vision may not always require a complete
understanding of the underlying causes of disease. Consider-
able progress in dissecting molecular pathways involved with
RGC death in a number of preclinical models of human diseases
has been made,1,2 although translational testing in humans with
various optic neuropathies has been slow to follow.
A related area of considerable interest is RGC-type specific-
ity. Retinal ganglion cells can be divided into different types
based on morphology, receptive field properties, and more
recently, by genetic markers.3,4 Important questions were
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identified as high priority: do different RGC types exhibit
varying degrees of vulnerability to injury or disease? Do some
types show more regenerative capacity than others?
Axon Growth
Both short (across an injury site) and long distance growth
(back to central visual targets) must be addressed and may
involve separate signaling pathways. Considerable progress has
been made in identifying candidate molecules that stimulate
axons to grow across an optic nerve injury site.5,6 Manipula-
tion of local glial, vascular, and inflammatory responses all
deserve additional attention, and testing combinatorial thera-
pies and evaluating the quality of regenerative growth,
including axon guidance, remain largely unexplored and
should represent a major objective of the AGI. Indeed, the
next major challenge is to encourage long distance growth to
appropriate targets while minimizing aberrant growth and
sprouting.7,8 While much progress has been made to under-
stand the mechanisms underlying guidance, target selection,
and synapse formation of developing axons, little is known
about how regenerating axons perform after injury.6,9,10
Workshop participants generally dismissed the requirement
that regenerative axon growth should necessarily recapitulate
developmental patterning regarding pathway choice, target
selection from the dozen different subcortical targets for
regenerating RGCs to choose from,11 or specificity of synaptic
connectivity.12 In regenerating axons, what steps need to be
taken to prevent an aberrant projection from developing and
innervating the spared/undamaged retina or inappropriate
areas in the brain? Since target selection is cell-type specific,
getting specific RGC types to innervate the appropriate target
and become reintegrated into existing or remodeled circuits
may be crucial, although questions on circuit reintegration in
the adult are largely unstudied. Thus, it will be important to
identify guidance cues and synapse formation signaling
pathways in a regenerative environment. Indeed, some axon
growth–promoting regenerative therapies may introduce
guidance or synapse formation problems, while others may
not, suggesting that all regenerative therapies may not be
equal. Within this context, however, there was discussion that
RGC innervation of brain targets subserving image formation
may be more important than promoting regeneration of RGCs
dedicated to non–image-forming functions such as pupillary
light response or photoentrainment of circadian rhythm.
GAPS IN SCIENTIFIC KNOWLEDGE AND BARRIERS TO
PROGRESS
The workshop’s subsequent focus was to identify and
elaborate on the present gaps of knowledge in the area of
optic nerve regeneration; these are summarized in Table 1.
Closely related to these gaps in knowledge was the discussion
of which of these are significant barriers to progress,
summarized in Table 2. Overcoming these gaps will help bring
scientists together across disciplines to make major progress
toward optic nerve regeneration and vision restoration.
TRANSLATION TO HUMAN DISEASE
Perhaps most limiting in reaching the goal of restoring vision in
humans is the lack of translational research and early phase
human testing in RGC survival and regeneration. Research
across other body systems has already demonstrated that
human testing is extremely important, and certainly human
patients with optic nerve diseases are eager to participate in
appropriately vetted trials of new therapeutic candidates. Such
initial testing of candidate therapies in humans will begin to
address critical questions, such as: How important are fine
points of circuit integration? Is it enough to give someone light
perception or improve contrast sensitivity? Functional im-
TABLE 1. Gaps in Knowledge and Other Unknowns
Lack of information about mechanisms underlying disease and injury-
related regeneration
Why do retinal axons exhibit a weak capacity to regenerate? Are
RGCs unique in their inability to regenerate?
How do retinal axons regenerate? What are the mechanisms of
transport and trafficking?
Is regeneration of RGC type-specific?
What is the role of RGC activity after injury?
What are the relevant cues that guide long-range growth, target
selection, and synapse formation?
How do nonneuronal factors, such as glia or extracellular matrices,
influence regeneration?
Experimental models: standards and uniformity
Optic nerve crush (useful to evaluate regenerative therapies, but
far less common in humans than ischemic or pressure-induced
injuries)
Intraocular pressure (good for quantifying cell death and axon loss
but less reproducible and more challenging for studying
regenerative growth or restoration of vision)
Ischemic optic neuropathies (reproducible but less well studied)
Cell culture models
Timing of delivery of therapies, importance of finding ‘‘postinjury’’
efficacy
Comparative and standardization issues (age, onset of injury,
response to injury)
Animal Models
Species selection: utility of fish, rabbit, rodent, non-human primate
models
Need for translational bridges to humans
Early-phase human testing to help define goals and approaches
Outcomes
Behavioral assays linking structure to function
How many neural connections are enough?
Can ‘‘vision’’ areas be targeted?
TABLE 2. Barriers to Progress/Current Needs
Science/Technology
Development of better functional and behavioral assays;
Improved viral/nonviral manipulation of inhibitory/regenerative
signaling pathways;
Validated molecular markers for primate and human retina;
Better tools/technologies to perform in vivo deep brain imaging;
More ‘‘omics’’ approaches to provide genomic and proteomic
resources for higher throughput screening and discovery research.
Nonscientific/Sociologic
Improved mechanisms to build teams or promote collaborative
research;
Improved communication of positive AND negative results;
Shared resources (e.g., core facilities for viruses, ultrastructure,
compound libraries, behavioral assays);
Dissemination of standard models.
Achieving final goals
Bridges from basic research to clinical research;
Begin early phase testing (need to learn from human patient
experiments);
Support to identify and test innovative human biomarkers of
regenerative biology.
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provement is a big step, but it will also be necessary to perform
human trials to learn how to measure axon regeneration and
visual restoration in patients. Similarly, the workshop partici-
pants noted that, as a field, we should think backwards from
the ‘‘clinic-of-the-future.’’ Having biomarkers for RGC function
will be extremely important, as will having a delivery system
with demonstrated safety. Moving treatments into human
testing was identified as something that could be done quickly,
within 5 years, and would help the field determine how to
conduct clinical trials in a shorter time frame.
A VIEW TO THE FUTURE
Based on workshop consensus, immediate goals should
include extending work to enhance regeneration in current
animal models, solving axon guidance and central targeting in
regeneration, and crossing into human testing for both
validating biomarkers and testing candidate therapies. Other
first-move approaches should include building resource
centers and expanding functional or behavioral testing assays
in preclinical models. The group appreciated that although
disease pathophysiology remains an important separate goal,
one therapeutic solution might ultimately address many
different optic neuropathies, and that identifying candidate
therapies should be a major focus of the AGI.
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